Therapeutic Response Statement (Sensitivity)
This therapeutic response statement supports the relationship that BRAF p.V600K status confers therapeutic sensitivity to Dabrafenib, Trametinib in patients with Non-Small Cell Lung Cancer.
The European Medicines Agency (EMA) has authorized trametinib in combination with dabrafenib for the treatment of adult patients with advanced non-small cell lung cancer with a BRAF V600 variant.
This statement is based on a regulatory approval from the European Medicines Agency:
Trametinib in combination with dabrafenib is indicated for the treatment of adult patients with advanced non-small cell lung cancer with a BRAF V600 mutation.